Skip to main content
. 2023 Apr 11;29(12):2299–2309. doi: 10.1158/1078-0432.CCR-22-3894

Figure 1.

Figure 1. Resistance to first-line therapy impairs the efficacy of second-line therapy. BRAFV600E-mutated colorectal cancer PDX models C5002 and C5003 were treated with FOLFIRI or encorafenib + cetuximab (Enco/cetux) until progression. Cross-over to alternate therapy until progression. A, In vivo sequencing of therapy model. B, Progression-free survival (PFS) of C5002 and C5003 for FOLFIRI first-line treatment and E+C second-line treatment (n = 4). C, PFS for E+C first-line treatment and FOLFIRI second-line treatment (n = 4). D, PFS for first and second-line FOLFIRI or E+C treatment. (*, P < 0.05)

Resistance to first-line therapy impairs the efficacy of second-line therapy. BRAFV600E-mutated colorectal cancer PDX models C5002 and C5003 were treated with FOLFIRI or encorafenib + cetuximab (Enco/cetux) until progression. Cross-over to alternate therapy until progression. A,In vivo sequencing of therapy model. B, Progression-free survival (PFS) of C5002 and C5003 for FOLFIRI first-line treatment and E+C second-line treatment (n = 4). C, PFS for E+C first-line treatment and FOLFIRI second-line treatment (n = 4). D, PFS for first and second-line FOLFIRI or E+C treatment. (*, P < 0.05)